Clinical Trial Update: Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicating completion of Phase 2 and Phase 3 studies assessing the efficacy and safety of Relaxin (serelaxin) for acute heart failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Relaxin (Relaxin)

Snippet

Sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies | Conditions: Heart Failure, Congestive | Phase 2, Phase 3 | Status: COMPLETED